1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Drugs In Development, 2022, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 51, 41, 2, 8, 88, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 13 and 2 molecules, respectively.
Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Systemic Lupus Erythematosus - Overview
- Systemic Lupus Erythematosus - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Systemic Lupus Erythematosus - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
- Systemic Lupus Erythematosus - Drug Profiles
- Systemic Lupus Erythematosus - Dormant Projects
- Systemic Lupus Erythematosus - Discontinued Products
- Systemic Lupus Erythematosus - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Systemic Lupus Erythematosus, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Systemic Lupus Erythematosus - Dormant Projects, 2022
- Systemic Lupus Erythematosus - Discontinued Products, 2022
- Number of Products under Development for Systemic Lupus Erythematosus, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abcentra LLC
- Accro Bioscience Suzhou Co Ltd
- Alexion Pharmaceuticals Inc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Aluda Pharmaceuticals Inc
- Amgen Inc
- Ampio Pharmaceuticals Inc
- Annexon Inc
- Apellis Pharmaceuticals Inc
- Apimeds Inc
- APT Therapeutics Inc
- Aqualung Therapeutics Corp
- Argenx SE
- Aria Pharmaceuticals Inc
- Asahi Kasei Pharma Corp
- AskGene Pharma Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Athos Therapeutics Inc
- Aurinia Pharmaceuticals Inc
- Avotres Inc
- BeiGene Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing Toll Biotech Co Ltd
- Bio-Path Holdings Inc
- BioAegis Therapeutics Inc
- Biocon Ltd
- Biogen Inc
- BioTherapeutics Inc
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Capricor Therapeutics Inc
- Captor Therapeutics SA
- Carna Biosciences Inc
- Cellenkos Inc
- CellionBioMed Inc
- Cells for Cells SA
- Centessa Pharmaceuticals Plc
- Centivax Inc
- ChemoCentryx Inc
- Chinook Therapeutics Inc
- Chong Kun Dang Pharmaceutical Corporation
- Chugai Pharmaceutical Co Ltd
- Citryll BV
- Corbus Pharmaceuticals Inc
- Corestem Inc
- Coya Therapeutics Inc
- CSL Ltd
- CSPC Pharmaceutical Group Ltd
- Cugene Inc
- CuraVac Inc
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Domainex Ltd
- Eisai Co Ltd
- Eledon Pharmaceuticals Inc
- Eli Lilly and Co
- Ermium Therapeutics SAS
- Evopoint Bioscience Co Ltd
- Exinda Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- Foshan Rexie Biotechnology Co Ltd
- Fresh Tracks Therapeutics Inc
- Galapagos NV
- Genentech USA Inc
- General Nanotherapeutics LLC
- Generos Biomedical Technology (Hangzhou) Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genesen Co Ltd
- Genovax Srl
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- Good T Cells Inc
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- H. Lundbeck AS
- HanAll Biopharma Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HemoGenyx Pharmaceuticals Plc
- Horizon Therapeutics Plc
- Huabo Biopharm (Shanghai) Co Ltd
- iCELL Biotechnology Co Ltd
- iCell Gene Therapeutics LLC
- Ichnos Sciences Inc
- Idorsia Pharmaceutical Ltd
- IL-2Rx Inc
- Iltoo Pharma
- Immplacate Inc
- Immune Modulation Inc
- Immungenetics AG
- ImmunoBiome Inc
- ImmunoQure AG
- Immunwork Inc
- Immupharma Plc
- Inflection Biosciences Ltd
- InnoCare Pharma Ltd
- Innovimmune Biotherapeutics Inc
- iSD Immunotech ApS
- JAMM Therapeutics Ltd
- Janus Biotherapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Jura Bio Inc
- Juventas Cell Therapy Ltd
- Kangpu Biopharmaceuticals Ltd
- Karyopharm Therapeutics Inc
- KeyMed Biosciences Inc
- Kezar Life Sciences Inc
- Kiniksa Pharmaceuticals Ltd
- Kyowa Kirin Co Ltd
- Landos Biopharma Inc
- Lead Discovery Center GmbH
- Lepton Pharmaceuticals Ltd
- MedAnnex Ltd
- MENTRIK Biotech LLC
- Merck & Co Inc
- Merck KGaA
- Microba Life Sciences Ltd
- MorphoSys AG
- Nanchang Hongyi Pharmaceutical Co Ltd
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nektar Therapeutics
- Neovacs SA
- Neutrolis Inc
- Novartis AG
- Nudge Therapeutics Inc
- Octagon Therapeutics Inc
- Octapharma AG
- OMass Therapeutics Limited
- Omeros Corp
- Orbsen Therapeutics Ltd
- PB Immune Therapeutics Co Ltd
- Pfizer Inc
- Pharchoice Therapeutics Inc
- Priovant Therapeutics Inc
- ProNoxis AB
- Provention Bio Inc
- Ra Pharmaceuticals Inc
- Regen BioPharma Inc
- Reistone Biopharma Co Ltd
- RemeGen Co Ltd
- Resolve Therapeutics LLC
- Rheos Medicines Inc
- Sanofi
- Sareum Holdings Plc
- Sarkana Pharma Inc
- SBI Biotech Co Ltd
- SciRhom GmbH
- Sengenics Corp Pte Ltd
- Serenity Bioworks Inc
- Shanghai GeneChem Co Ltd
- Shanghai Jiyu Pharmaceutical Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Simcere Pharmaceutical Group Ltd
- SinoMab Bioscience Ltd
- Slate Bio Inc
- Sorrento Therapeutics Inc
- Steel Therapeutics Inc
- StingInn LLC
- Swedish Orphan Biovitrum AB
- SynAct Pharma AB
- Takeda Pharmaceutical Co Ltd
- Tasly Biopharmaceuticals Co Ltd
- Technoderma Medicines Inc
- TherapyX Inc
- TolerogenixX GmbH
- Tonix Pharmaceuticals Holding Corp
- Transcenta Holding Ltd
- Twinpigbiolab Co Ltd
- UCB SA
- Usynova Pharmaceuticals Ltd
- Vera Therapeutics Inc
- Viracta Therapeutics Inc
- Visterra Inc
- Vitro Biopharma Inc
- XTL Biopharmaceuticals Ltd
- Zenas BioPharma (USA) LLC
- ZyVersa Therapeutics Inc
